Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131.

Abstract

10007 Background: Four-year disease free survival (DFS) for patients with B-ALL classified as VHR is approximately 70%. Strategies to improve DFS with intensive post-Induction therapy using fractio...